Egg white extract could help tame blood sugar and pressure
NCT ID NCT06555393
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether a peptide called IRW, found in egg white hydrolysate, can help manage high blood sugar and blood pressure. About 28 participants at risk for or with type 2 diabetes will consume a smoothie with the peptide on four separate days, while a healthy control group does it once. Researchers will measure peptide levels in the blood, along with glucose, insulin, and blood pressure changes over a few hours.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bioactive peptide IRW from egg white hydrolysate
- What this could lead to
- If it works, this could point toward a natural dietary supplement to help control blood sugar and blood pressure.
- What could go wrong
- This is a very small, early-phase study (28 people) looking at short-term effects only. The peptide may not show meaningful benefits or may not be absorbed well.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 28 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Healthy control group: * Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area/driving distance). * Normal weight (BMI below 25 kg/m2 or Asian population below 23 kg/m2 ) * Waist circumference below the following ethnic specific cut offs: Canada / USA: \<102 cm men and \<88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: \<94 cm men and \<80 cm women; Asians, Japanese, South and Central Americans: \<90 cm men and \<80 cm women * Fasting glucose \<5.6 mmol/L * HbA1c \<5.6 % * Blood pressure \<130/85 mmHg * Triglycerides \<1.7 mmol/L * HDL-Cholesterol \>1.03 mmol/L men and \>1.29 mmol/L women * Body weight stable (within 3% fluctuation) for at least 6 months prior to the study * Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago) Individuals at risk of diabetes/having type 2 diabetes: * Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area/driving distance). * Overweight or obesity (BMI above 25 kg/m2 or Asian population above 23 kg/m2) * Waist circumference at or above the following ethnic specific cut offs: Canada / USA: ≥ 102 cm men and ≥ 88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: ≥ 94 cm men and ≥ 80 cm women; Asians, Japanese, South and Central Americans: ≥ 90 cm men and ≥ 80 cm women * Fasting glucose ≥ 6.0 mmol/L * HbA1c ≥ 6.0 % * Body weight stable (within 3% fluctuation) for at least 6 months prior to the study * Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago) Exclusion Criteria: * Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia, with endocrine disorders other than T2D * Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines, and omega-3 supplements) * Pregnant/lactating women * Individuals aged above 70 years * Smokers (current smokers: daily/occasional and those who have smoked more than 100 cigarettes in their life) * Individuals with specific nutritional restrictions (e.g. vegetarianism excluding eggs from their diet, vegan or with egg allergy) will be excluded * Individuals with poorly controlled (HbA1c \>12.0%) diabetes or taking exogenous insulin will be excluded. Other anti-diabetic and lipid-lowering medications will be documented.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High blood pressure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2P5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Chatbot coach takes aim at diabetes risk after pregnancy